Peptide-Drug Conjugates

5 articles in this topic.

Complete Guides

Peptide-Drug Conjugates for Cancer

Peptide-drug conjugates deliver cytotoxic payloads directly to tumors using receptor-targeting peptides. Here is what the clinical evidence shows so far.

18 min read|Mar 20, 2026

All Articles

Peptide-Drug Conjugates

PDC Linker Chemistry: How the Connection Matters

Peptide-drug conjugate linker chemistry explained: cleavable vs non-cleavable linkers, enzyme-sensitive release, pH triggers, and clinical design strategies.

14 min read|Mar 25, 2026

Peptide-Drug Conjugates

RGD Peptide-Drug Conjugates for Tumor-Targeted Chemotherapy

How RGD peptides deliver chemotherapy to tumors via integrin receptors. Covers clinical trials, linker chemistry, iRGD penetration, and immunotherapy combos.

14 min read|Mar 25, 2026

Peptide-Drug Conjugates

Somatostatin PDCs: Hormone Receptors as Drug Addresses

Somatostatin receptor targeting delivers radiation directly to neuroendocrine tumors. From Lutathera to next-gen alpha emitters, this is the PDC frontier.

13 min read|Mar 25, 2026

Peptide-Drug Conjugates

PDCs vs Antibody-Drug Conjugates Compared

Peptide-drug conjugates offer deeper tumor penetration, lower immunogenicity, and simpler manufacturing than ADCs. Here's how the two platforms compare.

14 min read|Mar 22, 2026